Background: The purpose of the study was to determine the prevalence and associations of clinically relevant fatigue (CRF) in men with biochemically controlled prostate cancer on long-term androgen deprivation therapy (ADT). Results: Eight-one per cent (160 of 198) of questionnaires were analysable. CRF prevalence was 43% (68 of 160).
introduction
Prostate cancer is the commonest male cancer with 36 000 new cases diagnosed each year in the UK [1] . Androgen deprivation therapy (ADT) is the primary treatment for those with metastatic disease or those with locally advanced disease who are not suitable for surgery or radiotherapy. Adjuvant ADT is also given for 2-3 years after radiotherapy or surgery for those with high-risk locally advanced disease [tumour stage T3, Gleason grade ‡8 or prostate-specific antigen (PSA) ‡20 ng/ml] [2] . Long-term ADT is most commonly administered in the form of 3-monthly GnRH (gonadotropin-releasing hormone) analogue injections. When primary treatment fails, oral antiandrogens, stilbestrol or prednisolone can be added. In this way, prostate cancer can often be controlled for several years; treatment is continued until either the disease becomes hormone refractory or the patient dies of other causes.
ADT is known to be associated with a number of side-effects. These commonly include hot flushes, impotence and loss of libido and may also include gynaecomastia, hyperlipidaemia, decreased bone density, anaemia, muscle wasting, depression, increase in fat deposition and a decline in cognitive function [3, 4] . Anecdotally, patients receiving ADT commonly also complain of fatigue but there has been little research into this. While some studies have focused on quality-of-life outcomes and reported fatigue or vitality subscale measures [5] [6] [7] [8] , only two have used fatigue-specific assessment tools in men with prostate cancer receiving ADT alone. One prospective study (n = 62) found that fatigue increased after receiving 3 months of ADT [4] , but another (n = 23) found no increase in fatigue after 6 and 12 months of continuous ADT [9] . Limitations of these studies include small patient numbers, no data beyond 12 months treatment duration, potential confounding factors such as unaccounted for medical co-morbidities and the possible inclusion of men whose disease had escaped hormone control [9] . It is also unclear whether fatigue in this population is specifically associated with prostate cancer and ADT or simply age, depression, anxiety and the sleep-disrupting effect of prostatic symptoms. Furthermore, most studies have described only mean fatigue scores, which are difficult to translate into clinically useful information for clinicians and patients. It is more clinically meaningful to know the proportion of patients with fatigue of a severity that interferes with their functioning [a severity that we have chosen to define as clinically relevant fatigue (CRF)]. This is especially important because the use of ADT in prostate cancer is increasing [10] , treatment can continue for several years and men are being diagnosed at a younger age when the impact of treatment-related CRF could be particularly burdensome. We are not aware of any published studies regarding the prevalence of CRF in men receiving long-term ADT or the association with relevant variables such as extent of disease burden (metastatic versus localised to the prostate), psychological distress, other medical co-morbidities and age.
We therefore aimed to determine the prevalence and associations of CRF in men with biochemically controlled prostate cancer who are receiving long-term GnRH-based ADT. We hypothesised that CRF would be associated with having metastatic disease, poorer quality of life, depression, anxiety and pain.
patients and methods
This was a cross-sectional survey of men with biochemically controlled prostate cancer on long-term GnRH-based ADT. Data were collected by self-report questionnaires and supplemented with clinical data from medical records. The study was approved by the local research ethics committee.
The Edinburgh Cancer Centre, Queen Margaret Hospital in Dunfermline and the Royal Victoria Hospital in Kirkcaldy provide regional specialist multidisciplinary cancer care for men with prostate cancer in the county of Fife, UK, a geographically defined area of 362 000 people. All 3-monthly GnRH analogue injections are centrally coordinated and delivered by nurse specialists within this service (thus providing a geographically representative population sample). This also coincides with monitoring of patients' PSA. The sample size was based on the total number of patients who were receiving long-term GnRH-based ADT via this service at the time of the survey in [2005] [2006] . The medical notes of all 298 patients on the GnRH service computer database were screened. Patients were eligible and regarded as having biochemically controlled prostate cancer if they had been receiving GnRH analogues for at least 6 months; PSA < 0.2 lg/l within the last 3 months or if >0.2 lg/l then stable at nadir for two consecutive readings at least 3 months apart. Patients were excluded if they were receiving neoadjuvant ADT before radiotherapy or brachytherapy; had hormone-refractory prostate cancer; were noted to have dementia in their medical records or another concurrent cancer diagnosis (excluding basal cell skin carcinoma).
From November 2005 to February 2006, eligible patients were sent a postal questionnaire. Patients were invited to complete and return it using the stamped addressed envelope provided. Those who did not reply within 1 month were mailed again.
Data collected from medical records included age and postcode (to assess Scottish Index of Multiple Deprivation 2004 [11] , ranging one to five; most to least deprived based on population census data assessing income, employment, health, education/skills/training, housing, geographic access and telecommunications), PSA results and current disease status (metastatic or localised to prostate). Other medical conditions may influence fatigue, so patients were asked to report these by ticking a box if they had heart or breathing problems, diabetes, a stroke, problems with their bones or joints that limited mobility and also an open-ended question where they could describe other medical conditions they thought relevant [12] .
Fatigue was measured using the Brief Fatigue Inventory (BFI) [13] . This is a nine-item self-rated scale that includes three items concerning present, usual and worst severity of fatigue and six items concerning how much the fatigue interferes with general activity, mood, walking ability, normal work, relations with other people and enjoyment of life over the previous week. Each item is scored on an 11-point scale from 0 ('no fatigue'/'does not interfere') to 10 ('as bad as you can imagine'/'completely interferes'). The global BFI score is the arithmetic mean of all nine of these items (range 0-10). Mild, moderate and severe fatigue has been defined using only the single 'worst' or 'usual' fatigue severity items; the cut-off between mild and moderate fatigue lies between 3 and 4 [13] [14] [15] . Moderate fatigue severity is associated with distress and interference with functional activity [16] . The National Comprehensive Cancer Network recommends that patients with moderate fatigue require further clinical assessment [17] . In other words, this severity of fatigue is considered clinically relevant. In order to capture all the BFI data on both fatigue severity and interference with function, we applied this cut-off to the BFI global score and defined moderate/severe or CRF as global BFI >3, a threshold also used in previous studies [18, 19] .
The worst pain experienced in the previous week was rated on an 11-point scale between 0 ('no pain') and 10 ('pain as bad as you can imagine'). Scores ‡4 represent at least moderate pain [20] .
Anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS), a self-rated 14-item scale relating to the last week [21] . Each item can be answered on a four-point scale (0-3) generating a total between 0 and 21 for both subscales. Recommended cutoff scores for clinically likely cases of anxiety ( ‡9) or depression ( ‡8) were applied [22] .
Urinary symptoms were assessed using the International Prostate Symptom Score, a seven-item scale. Each item is rated on six points (0-5), giving a score of 0-35. Scores ‡8 represent moderate to severe symptoms [23] . Patients with a urinary catheter were instructed not to complete this.
Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQc30 version 3.0) [24] . To reduce questionnaire burden and avoid replication of themes, only the following functioning subscales (physical, role and social) and symptom subscales were used (fatigue, nausea and vomiting, insomnia, constipation and diarrhoea). Each item relates to the past week and is answered on a four-point scale: not at all, a little, quite a bit, very much. Two overall health and quality-of-life items are rated on a seven-point scale (1) (2) (3) (4) (5) (6) (7) . In accordance with the scoring manual, scores were transformed to a 0-100 scale; higher scores represent a better level of functioning or a worse level of symptoms.
Likert scales for hot flushes and sore nipples/breasts were constructed based on EORTC QLQc30 format and scoring.
data analysis
For missing data, the mean score was used to impute European Organisation for Research and Treatment of Cancer (EORTC) and BFI items when >50% of the scale was completed [25] . To assess whether participating patients were representative of the eligible sample, participants and non-participants were compared using Student's t-tests and Chisquared tests as appropriate. The prevalence of CRF [with 95% confidence intervals (CIs)] was calculated. Univariate associations of CRF were examined using Student's t-tests for continuous variables and binary logistic regression for categorical variables (reported using odds ratios (ORs) and 95% CIs). EORTC symptoms were categorised as none versus some. Independent associations of CRF were examined using multivariate binary logistic regression. No variable selection was used, and all relevant 
results
Of 198 eligible patients, 160 questionnaires were analysable (81% participation rate; Figure 1 ). Only 0.05% of data were missing. There were no statistically significant demographic or clinical differences between participants and nonparticipants. The mean age was 77.2 years [standard deviation (SD) 7.5]. The median duration of GnRH-based ADT was 26 months (range 6-30), 8% (12 of 160) were receiving adjuvant ADT, 81% (129 of 160) were on first-line ADT [54% (87 of 160) for locally advanced disease; 25% (40 of 160) for metastatic disease; 1% (2 of 160) for disease status unknown], 11% (17 of 160) were receiving second-line ADT [8% (12 of 160) for localised disease; 3% (5 of 160) for metastatic disease] and 0.5% (1 of 160) each were on third-and fourth-line ADT for metastatic disease. Sixty-nine per cent (111 of 160) had locally advanced disease (Table 1) . Table 2 shows the self-report measures.
prevalence and univariate analysis of associations of CRF
The prevalence of CRF in men with biochemically controlled prostate cancer on long-term GnRH-based ADT was 43% (68 of 160, 95% CI 35% to 50%). Mean global BFI was 3.1 (SD 2.4). There was no statistically significant difference in the prevalence of CRF between men with locally advanced and metastatic disease (OR 1.8, 95% CI 0.9-3.7, P = 0.10).
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CRF was more common in men who had depression (OR 9.8, decreasing to 8.4 once the confounding HADS fatigue item was excluded), anxiety, moderate/severe pain, moderate/severe urinary symptoms and concurrent co-morbidities (Table 3) 
independent associations of CRF
To determine independent associations of CRF, other potentially clinically relevant variables (age, urinary symptoms, co-morbidities, anxiety, depression, disease status and pain scores) were entered into a multivariate logistic regression: moderate/severe pain and depression were the only independent associations of CRF (OR 3.0 and 4.9, respectively; original articles Annals of Oncology Table 3 ) after controlling for the other factors. To see if the HADS fatigue item was confounding the relationship with CRF, a second regression was carried out excluding this question. This resulted in moderate/severe pain being the only independent association with CRF (OR 4.4; Table 3 ).
discussion main findings
To our knowledge, this is the first study to focus on CRF in men with biochemically controlled prostate cancer on longterm GnRH-based ADT. The main findings were as follows: (i) the prevalence of CRF in the sample was 43% (95% CI 35% to 50%) and patients with CRF had worse quality of life and poorer functioning than those without. The difference in scores between those with and without CRF far exceeded the 20 points described as a 'large' clinically significant difference [26] illustrating the major impact of CRF on the life of patients; (ii) CRF was associated with moderate/severe pain, depression, anxiety, concurrent co-morbidities and moderate/severe urinary symptoms but the only independent associations of CRF were depression and pain. There are no normative UK BFI data to compare with, so it is unclear whether CRF prevalence in men with biochemically controlled prostate cancer on longterm GnRH-based ADT is different from similarly aged men in the general population. However, mean EORTC fatigue subscale general population data for Swedish and German men aged >70 years are lower than that of our sample (21.5, 27.8 and 35, respectively [27, 28] ) suggesting that ADT or cancer may worsen fatigue. Pain, depression and fatigue are a common symptom cluster in cancer patients [29] . In this cohort, pain was most likely to have been a mixture of cancer-related bone pain and chronic degenerative pain. Depression has been previously reported to be associated with CRF [30, 31] and depression is also more common in hypogonadal men [32] . However, CRF and depression are not equivalent because only 52% of patients with CRF had depression according to our criteria (HADS ‡8); and this dropped to 22% once the confounding HADS item was removed. These results should be interpreted with caution because the effect of removing the contribution of the HADS fatigue item to the HADS depression score made the definition of depression more stringent and consequently the depression group became smaller (18 patients). However, other authors have used case definition thresholds for depression as high as 11 [22] .
The clinical impression that patients with greater tumour burden experience higher levels of fatigue was not confirmed in this study. Urinary symptoms such as nocturia, which may disrupt sleep, are known to be associated with fatigue [33] and this was found to be the case in our sample.
other literature
Comparisons with other literature are hindered by the wide variety of fatigue measures used and populations studied. Only two studies have specifically examined fatigue in men receiving ADT.
The first of these studies prospectively assessed fatigue in 62 men receiving GnRH analogues for 3 months [4] either as their primary treatment or as neoadjuvant treatment before radiotherapy. The study found a statistically significant increase in fatigue scores over 3 months on six of the eight scales used but not on the EORTC fatigue subscale, which remained unchanged (median 22/100, range 0-89) and was lower than that of our cohort (median 33, range 0-100). They also found that muscle mass decreased but there was no change in selfreported functional measures or psychological distress. While this study was prospective and objectively measured surrogate markers of fatigue such as grip strength, follow-up was only for 3 months; so the effect of long-term GnRH-based ADT on fatigue could not be determined.
The second smaller study was of longer duration and assessed 23 men on continuous GnRH analogues but found no significant change in fatigue (or depression) between baseline, 6 and 12 months [9] .
Both these studies were small, did not account for medical co-morbidities (which may be a confounder) and the duration of ADT treatment studied was short compared with the present study (median 26 months). Several other studies have described quality-of-life outcomes in men receiving ADT. A recent report of 76 men with nonmetastatic prostate cancer on continuous ADT found a decline in physical function and the Short Form-36 (SF-36) vitality subscale over 12 months. Most of this effect had occurred by 3 months and stayed relatively stable thereafter [34] . Other studies have examined men with locally advanced or lymph node-positive prostate cancer, comparing men who had ADT versus no treatment. None of these used a fatiguespecific measure but generally found SF-36 vitality was lower and EORTC fatigue was statistically significantly higher in those who received ADT [5, 7, 8] .
limitations There were several limitations to our study: (i) The prevalence of CRF may be an underestimate because some patients may not have participated because they were too ill or fatigued to do so. However, there was a good response rate to the survey (81%), and there were no statistical differences between the demographic and clinical characteristics of those who did and did not participate; (ii) In common with all cross-sectional studies, we could only offer a 'snap shot'; prospective studies are required to fully understand the incidence and trajectory of CRF in patients receiving long-term GnRH-based ADT; (iii) Using proposed cut-offs for continuous variables (such as BFI global fatigue and HADS anxiety and depression) while making the results more clinically meaningful can reduce the statistical power of detecting a relationship between a variable and outcome [35] ; (iv) We used a cut-off of >3 on the global BFI score to define CRF. We acknowledge that other cut-off scores could have been chosen. However, there is no universally agreed definition of CRF in this population and we used a severity both justified by clinical guidelines and previously used by other researchers; (v) HADS cut-off scores are not the same as an interview-defined case definition of depression or anxiety; (vi) Asking patients about their other medical Annals of Oncology original articles conditions relied heavily on the patient's interpretation of the questions and recall/understanding of their medical history; (vii) Some studies have previously reported that men on ADT for 3 months had a drop of haemoglobin [36, 37] . While the patients in this study had been on treatment for longer than that, we were unable to check the haemoglobin of our sample due to the postal nature of our survey.
future implications
The use of GnRH-based ADT in prostate cancer is increasing in both the adjuvant and the palliative setting [10] but it is recognised to have a detrimental effect on quality of life. Several factors may contribute to this, many of which are treatable. Fatigue may be attenuated if clinicians ensured depression was treated and pain was controlled. Physical function is adversely affected by fatigue, and associated disability also places an added burden on caregivers. Exercise may help maintain muscle bulk and has been shown to attenuate fatigue in men with prostate cancer [38, 39] . Interestingly, maintenance of physical function has also been shown to be associated with improved survival [40] . Clinicians could also consider pharmaceutical interventions such as methylphenidate, though these also have toxic effects [41] . Together with the other side-effects of ADT, the adverse impact on quality of life and the debateable survival benefits of immediate continuous treatment, there is an argument that intermittent ADT may be reasonable for some patients [42] .
conclusions Two-fifths of men with biochemically controlled prostate cancer on long-term GnRH-based ADT had CRF that impaired function and was associated with poorer quality of life. Depression and pain were independent associations of fatigue suggesting attention needs to be paid to improved management of psychological factors and pain in order to improve fatigue and optimise functional ability and quality of life in these men.
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